Bipolar Disorder Biobank

Researchers have established a large-scale Bipolar Disorder Biobank, collecting both biological samples and clinical data from 2,000 individuals. This biobank is structured to help researchers facilitate studies on disease risk and pharmacogenomic probes using state-of-the-art research technology.

The identification of genetic risk factors associated with disease onset can potentially lead to early intervention and treatment in at-risk patients. Early intervention is particularly important in bipolar disorder because the initiation of any treatment is often delayed by more than a decade. Additionally, identification of pharmacogenomic predictors of treatment response could provide increased selectivity to treatment recommendations, as well as help prevent serious adverse events, such as antidepressant-induced mania.

This is a multisite endeavor, with Mayo Clinic in Rochester, Minn., serving as the primary project site. Other sites assisting in the recruitment of participants include Mayo Clinic in Florida; Mayo Clinic in Arizona; Mayo Clinic Health System in Austin, Minn.; the Lindner Center of HOPE in Mason, Ohio, and the University of Minnesota.